5 天之前 · Mitsubishi Tanabe Pharma America Announces Research Collaboration Between Mitsubishi Tanabe Pharma Corporation and Dewpoint Therapeutics to Advance Small Molecule Condensate Modulator for ALS Read More

2022年10月12日 · Mitsubishi Tanabe Pharma America is driving discovery every day through smart science with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases. Learn More

2024年12月4日 · Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC). It was established by MTPC to develop and advance our pipeline as well as commercialize approved pharmaceutical products in North America.

JERSEY CITY, N.J. December 3, 2024 – Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced 10 presentations covering advances in amyotrophic lateral sclerosis (ALS) research at the Motor Neurone Disease Association (MNDA) 35 th International Symposium on ALS/MND, being held in Montreal, Canada, from December 6-8.

JERSEY CITY, N.J. January 29, 2025 – Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the publication of a retrospective analysis of real-world data in the Journal of Comparative Effectiveness Research (JCER).

For more than 300 years, our parent company, Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, has proudly pursued medical advances; we’ve discovered and produced several first in class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM) and amyotrophic lateral sclerosis (ALS).

JERSEY CITY, N.J. October 17, 2024 – Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that twelve presentations following expansive research in amyotrophic lateral sclerosis (ALS) will be shared as part of the Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) 2024 Annual Meeting, being held virtually October 21-24.

JERSEY CITY, N.J. October 6, 2024 – Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced two presentations at the 2024 National Association of Specialty Pharmacy (NASP) Annual Meeting and Expo being held in Nashville, T.N., October 6-9.

JERSEY CITY, N.J. May 16, 2024 – Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced two presentations on investigational ND0612 in Parkinson’s disease (PD) will be shared at the International Association of Parkinsonism and Related Disorders (IAPRD) XXIX World Congress on Parkinson’s Disease and Related Disorders, being held in ...

2024年9月17日 · Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC). It was established by MTPC to develop and advance our pipeline as well as commercialize approved pharmaceutical products in North America.